NCT04807777View on ClinicalTrials.gov

Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

April 4, 2023

Study Completion Date

October 4, 2023

Conditions

Advanced Cutaneous Squamous Cell Carcinoma

Interventions

DRUG

Ruxolitinib

Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

Columbia University

OTHER